CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Exercise or conversion 10b5-1 | +4,351 | $3.98 | $17K | 66,722 |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −4,351 | $23.38 | $102K | 62,371 |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −4,351 | 26,947 | ||
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Exercise or conversion 10b5-1 | +2,175 | $3.98 | $9K | 64,546 |
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,175 | $20.00 | $44K | 62,371 |
| 2026-06-23 | Champoux Jennifer Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −2,175 | 31,298 | ||
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Exercise or conversion 10b5-1 | +2,176 | $3.98 | $9K | 64,547 |
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,176 | $19.00 | $41K | 62,371 |
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −2,176 | 33,473 | ||
| 2026-05-27 | Champoux Jennifer Chief Operating Officer | Exercise or conversion 10b5-1 | +2,175 | $3.98 | $9K | 64,546 |
| 2026-05-27 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,175 | $20.00 | $44K | 62,371 |
| 2026-05-27 | Champoux Jennifer Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −2,175 | 35,649 | ||
| 2026-05-22 | Champoux Jennifer Chief Operating Officer | Exercise or conversion 10b5-1 | +2,176 | $3.98 | $9K | 64,547 |
| 2026-05-22 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −2,176 | $19.00 | $41K | 62,371 |
| 2026-05-22 | Champoux Jennifer Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −2,176 | 37,824 | ||
| 2026-01-05 | Champoux Jennifer Chief Operating Officer | Sale | −2,629 | $15.17 | $40K | 62,371 |
| 2026-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award | +35,000 | 65,000 | ||
| 2026-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +158,000 | 158,000 | ||
| 2025-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award | +30,000 | 30,000 | ||
| 2025-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 |
Page 1 of 2 · 21 trades